Researchers Identify First Mutation to Explain Resistance to Venetoclax

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights - Leukemia
Phoebe Starr

San Diego, CA—The BCL2 Gly101Val mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia (CLL). The BCL2 Gly101Val mutation is unique to CLL and so far has not been described in other cancers.

“Despite the effectiveness of venetoclax, a majority of patients will relapse. Up until now, we had no idea why. The discovery of a genetic mutation that confers resistance to venetoclax offers an explanation of why venetoclax stops working in some patients,” said lead investigator Piers Blombery, MBBS, Consultant Haematologist, Peter MacCallum Cancer Centre, Melbourne, Australia.

“We have shown that in some cases the mutation can be detected in patients’ bone marrow years before clinical signs of relapse appear,” Dr Blombery told listeners at ASH 2018.

“The molecular basis of venetoclax resistance is largely unknown for patients with CLL who progress and for those who go on to Richter’s transformation,” Dr Blombery continued.

Acquired Resistance Mutation

The study was based on 67 patients with relapsed CLL who received treatment with venetoclax in 3 early clinical trials: 21 with CLL-like progression, 18 with Richter’s transformation, and 28 with no disease progression.

Of the 21 patients with CLL progression, 15 had samples suitable for genetic analysis with next-generation sequencing (NGS) on a panel of 33 genes; NGS was done before patients started treatment with venetoclax and when resistance developed.

BCL2 Gly101Val was identified in 4 patients with CLL progression while receiving venetoclax, but it was absent in samples from these 4 patients before starting venetoclax therapy, demonstrating that it is an acquired mutation associated with venetoclax.

BCL2 Gly101Val was not found in samples from over 400 patients with other hematologic malignancies. We also didn’t find it in any CLL patient not exposed to venetoclax. It is associated with a 180-fold decrease in the affinity to bind to the BCL2 protein,” Dr Blombery explained. “Of note, BCL2 Gly101Val is subclonal; that is, it is detectable in patients before overt clinical relapse,” he added.

“The mutation appears after at least 20 months of venetoclax therapy, so it is a late mutation. Wherever it was detectable, the patient progressed to clinical relapse,” he continued.

Additional Mutations Identified

BCL2 Gly101Val is not the only mutation that contributes to resistance. BCL2 Gly101Val was present in 75% of cells, but 25% were not driven by this mutation, and other mutations were identified in those cells.

“The fact that BCL2 Gly101Val is subclonal implicates multiple mechanisms of venetoclax resistance in the same patient,” Dr Blombery said.

“This provides a strong rationale for time-limited venetoclax, which several researchers are exploring. When you give patients a highly selective targeted agent like venetoclax, it doesn’t take long for resistance to develop. The mutation popped up before 2 years of therapy, so we think that is a reasonable time to stop the venet­oclax,” Dr Blombery stated.

“Patients can be screened for BCL2 Gly101Val while on venetoclax. If the mutation is detected, it would be prudent for the hemato­logist to begin to think about other therapies to use,” Dr Blombery commented.

“Perhaps a more aggressive combination therapy should be used. This disease has multiple genomic tricks up its sleeve,” he told listeners.

Related Items
November 4, 2019 — Oncology News & Updates
Yvette Florio Lane
Web Exclusives published on November 5, 2019 in In the News, Leukemia
MONALEESA-7 Sets New Standard of Care for Premenopausal Advanced Breast Cancer: Adding CDK4/6 to Endocrine Therapy Extends Survival
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Breast Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with Germline BRCA Mutation
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Pancreatic Cancer
FDA Unveils Oncology-Specific “Project Facilitate,” Expanding Access to Investigational Cancer Drugs
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Value-Based Care
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Last modified: February 27, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME